WeightLossDrugs News & Analysis
2 articles
Market Mood
Ozempic Patent Expiration Leads to Affordable Generics in India
Novo Nordisk's semaglutide, branded as Ozempic, is going off patent, allowing Indian manufacturers to produce generics. The generic versions are expected to cost around $14 in India. This shift may significantly reduce costs for millions of consumers globally, as these generics become available. The absence of such generics in the US market due to patent protection highlights potential disparities in drug pricing between countries. The move could influence weight-loss drug markets and alter competitive dynamics.
Read More
Restaurant Stocks Struggle in 2026 Amid Inflation and Weight-Loss Drug Impact
Restaurant stocks have faced significant challenges at the beginning of 2026, attributed to ongoing inflation, uneven economic growth, and the rising popularity of weight-loss medications. This environment raises concerns for investors, as consumer spending in the dining sector may decrease. Key data points indicate a potential decline in foot traffic, which could further impact earnings for restaurant companies. Analysts suggest that this may create selective buying opportunities for investors willing to take calculated risks in a turbulent market.
Read More